{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T08:40:37Z","timestamp":1780735237169,"version":"3.54.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"DOI":"10.1186\/s13098-025-01927-x","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T02:54:34Z","timestamp":1756263274000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Economic evaluation of liraglutide vs dulaglutide or oral semaglutide in patients with type 2 diabetes mellitus: a systematic review"],"prefix":"10.1186","volume":"17","author":[{"given":"Lu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinglin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"issue":"Supplement1","key":"1927_CR1","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.2337\/dc14-S081","volume":"37","author":"American Diabetes Association","year":"2014","unstructured":"American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37(Supplement1):S81\u201390.","journal-title":"Diabetes Care"},{"issue":"9922","key":"1927_CR2","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/S0140-6736(13)62154-6","volume":"383","author":"SE Kahn","year":"2014","unstructured":"Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014;383(9922):1068\u201383.","journal-title":"Lancet"},{"issue":"4","key":"1927_CR3","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1080\/14737167.2022.2042255","volume":"22","author":"Z Ruan","year":"2022","unstructured":"Ruan Z, Zou H, Lei Q, Ung COL, Shi H, Hu H. Pharmacoeconomic evaluation of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus: a systematic literature review. Expert Rev PharmacoEcon Outcomes Res. 2022;22(4):555\u201374.","journal-title":"Expert Rev PharmacoEcon Outcomes Res"},{"issue":"10467","key":"1927_CR4","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/S0140-6736(24)02317-1","volume":"404","author":"B Zhou","year":"2024","unstructured":"Zhou B, Rayner AW, Gregg EW, Sheffer KE, Carrillo-Larco RM, Bennett JE, et al. Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants. Lancet. 2024;404(10467):2077\u201393.","journal-title":"Lancet"},{"key":"1927_CR5","unstructured":"International Diabetes Federation. IDF Diabetes Atlas. 10th edition. Brussels: International Diabetes Federation; 2021."},{"issue":"10440","key":"1927_CR6","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1016\/S0140-6736(24)00685-8","volume":"403","author":"SE Vollset","year":"2024","unstructured":"Vollset SE, Ababneh HS, Abate YH, Abbafati C, Abbasgholizadeh R, Abbasian M, et al. Burden of disease scenarios for 204 countries and territories, 2022\u20132050: a forecasting analysis for the global burden of disease study 2021. Lancet. 2024;403(10440):2204\u201356.","journal-title":"Lancet"},{"issue":"7","key":"1927_CR7","first-page":"1141","volume":"15","author":"A Malone","year":"2024","unstructured":"Malone A. Diabetes and its economic repercussions. J Diabetes Metab. 2024;15(7):1141.","journal-title":"J Diabetes Metab"},{"issue":"12","key":"1927_CR8","doi-asserted-by":"publisher","first-page":"e1098","DOI":"10.1016\/S2468-2667(24)00251-2","volume":"9","author":"Y Xu","year":"2024","unstructured":"Xu Y, Lu J, Li M, Wang T, Wang K, Cao Q, et al. Diabetes in China part 2: prevention, challenges, and progress. Lancet Public Health. 2024;9(12):e1098\u2013104.","journal-title":"Lancet Public Health"},{"key":"1927_CR9","unstructured":"Chinese Center for Disease Control and Prevention. 2008 [cited 2025 Feb 17]. Available from: http:\/\/www.nhc.gov.cn\/jkj\/s10038\/201507\/810f1eda0db9440db05bf9ecf36aaebf.shtml"},{"issue":"9548","key":"1927_CR10","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","volume":"368","author":"DJ Drucker","year":"2006","unstructured":"Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696\u2013705.","journal-title":"Lancet"},{"key":"1927_CR11","doi-asserted-by":"crossref","unstructured":"Westermeier F, Fisman EZ. Glucagon like peptide-1 (GLP-1) agonists and cardiometabolic protection: historical development and future challenges. Cardiovasc Diabetol. 2025;24(1).","DOI":"10.1186\/s12933-025-02608-9"},{"issue":"9","key":"1927_CR12","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1111\/dom.14765","volume":"24","author":"M Kellerer","year":"2022","unstructured":"Kellerer M, Kaltoft MS, Lawson J, Nielsen LL, Strojek K, Tabak \u00d6, et al. Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to Metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trial. Diabetes Obes Metabolism. 2022;24(9):1788\u201399.","journal-title":"Diabetes Obes Metabolism"},{"issue":"4","key":"1927_CR13","doi-asserted-by":"publisher","first-page":"W","DOI":"10.7326\/0003-4819-151-4-200908180-00136","volume":"151","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W\u201365.","journal-title":"Ann Intern Med"},{"issue":"sup1","key":"1927_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13696998.2021.2014721","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. J Med Econ. 2022;25(sup1):1\u20137.","journal-title":"J Med Econ"},{"key":"1927_CR15","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1186\/s12882-024-03901-7","volume":"25","author":"L Wang","year":"2024","unstructured":"Wang L, Wang Y, Zhao Q. Economic evaluation of adding Dapagliflozin to standard care in the treatment of chronic kidney disease: a systematic review. BMC Nephrol. 2024;25:465.","journal-title":"BMC Nephrol"},{"issue":"2","key":"1927_CR16","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","volume":"16","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated health economic evaluation reporting standards (CHEERS)-Explanation and elaboration: A report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health. 2013;16(2):231\u201350.","journal-title":"Value Health"},{"issue":"1","key":"1927_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1332\/174426410X482999","volume":"6","author":"I Shemilt","year":"2010","unstructured":"Shemilt I, Thomas J, Morciano M. A web-based tool for adjusting costs to a specific target currency and price year. Evid Policy. 2010;6(1):51\u20139.","journal-title":"Evid Policy"},{"issue":"11","key":"1927_CR18","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1016\/j.clinthera.2021.08.015","volume":"43","author":"NA Risebrough","year":"2021","unstructured":"Risebrough NA, Baker TM, Zhang L, Ali SN, Radin M, Dang-Tan T. Lifetime Cost-effectiveness of oral semaglutide versus dulaglutide and liraglutide in patients with type 2 diabetes inadequately controlled with oral antidiabetics. Clin Ther. 2021;43(11):1812\u2013e267.","journal-title":"Clin Ther"},{"key":"1927_CR19","doi-asserted-by":"publisher","first-page":"1226778","DOI":"10.3389\/fphar.2023.1226778","volume":"14","author":"Z Feng","year":"2023","unstructured":"Feng Z, Tong WK, Zhang X, Tang Z. Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China. Front Pharmacol. 2023;14:1226778.","journal-title":"Front Pharmacol"},{"key":"1927_CR20","doi-asserted-by":"crossref","unstructured":"Malkin SJP, Hunt B, Huisman EL, Grand TS, Chubb B. The long-term cost-effectiveness of oral semaglutide in the Netherlands based on the PIONEER 2, 3 and 4 randomized controlled trials. Diabetes Res Clin Pract. 2021;175.","DOI":"10.1016\/j.diabres.2021.108759"},{"issue":"4","key":"1927_CR21","doi-asserted-by":"publisher","first-page":"455","DOI":"10.18553\/jmcp.2021.27.4.455","volume":"27","author":"GF Guzauskas","year":"2021","unstructured":"Guzauskas GF, Rind DM, Fazioli K, Chapman RH, Pearson SD, Hansen RN. Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes. J Managed Care Specialty Pharm. 2021;27(4):455\u201368.","journal-title":"J Managed Care Specialty Pharm"},{"issue":"7","key":"1927_CR22","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.1007\/s12325-022-02156-8","volume":"39","author":"J Franch-Nadal","year":"2022","unstructured":"Franch-Nadal J, Malkin SJP, Hunt B, Mart\u00edn V, Gallego Est\u00e9banez M, Vidal J. The Cost-Effectiveness of oral semaglutide in spain: A Long-Term health economic analysis based on the PIONEER clinical trials. Adv Therapy. 2022;39(7):3180\u201398.","journal-title":"Adv Therapy"},{"issue":"1","key":"1927_CR23","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s13300-019-00736-6","volume":"11","author":"SC Bain","year":"2019","unstructured":"Bain SC, Hansen BB, Malkin SJP, Nuhoho S, Valentine WJ, Chubb B, et al. Oral semaglutide versus empagliflozin, sitagliptin and liraglutide in the UK: Long-Term Cost-Effectiveness analyses based on the PIONEER clinical trial programme. Diabetes Therapy. 2019;11(1):259\u201377.","journal-title":"Diabetes Therapy"},{"key":"1927_CR24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.vhri.2016.10.006","volume":"14","author":"P Lasalvia","year":"2017","unstructured":"Lasalvia P, Baquero L, Ot\u00e1lora-Esteban M, Casta\u00f1eda-Cardona C, Rosselli D. Cost effectiveness of dulaglutide compared with liraglutide and glargine in type 2 diabetes mellitus patients in Colombia. Value Health Reg Issues. 2017;14:35\u201340.","journal-title":"Value Health Reg Issues"},{"issue":"12","key":"1927_CR25","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1080\/13696998.2016.1203329","volume":"19","author":"LH Chuang","year":"2016","unstructured":"Chuang LH, Verheggen BG, Charokopou M, Gibson D, Grandy S, Kartman B. Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective. J Med Econ. 2016;19(12):1127\u201334.","journal-title":"J Med Econ"},{"key":"1927_CR26","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.vhri.2022.07.005","volume":"32","author":"M Ekhlasi","year":"2022","unstructured":"Ekhlasi M, Taheri S, Yousefi N. Cost-Effectiveness of dulaglutide versus liraglutide for management of type 2 diabetes mellitus in Iran. Value Health Reg Issues. 2022;32:54\u201361.","journal-title":"Value Health Reg Issues"},{"key":"1927_CR27","doi-asserted-by":"crossref","unstructured":"Yuan S, Wu Y. Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model. Front Public Health. 2023;11.","DOI":"10.3389\/fpubh.2023.1201818"},{"issue":"5","key":"1927_CR28","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1080\/13696998.2016.1275651","volume":"20","author":"T Dilla","year":"2017","unstructured":"Dilla T, Alexiou D, Chatzitheofilou I, Ayyub R, Lowin J, Norrbacka K. The cost-effectiveness of dulaglutide versus liraglutide for the treatment of type 2 diabetes mellitus in Spain in patients with BMI\u2009\u2265\u200930 kg\/m2. J Med Econ. 2017;20(5):443\u201352.","journal-title":"J Med Econ"},{"issue":"6","key":"1927_CR29","first-page":"718","volume":"35","author":"ZY Xie","year":"2024","unstructured":"Xie ZY, Li MT, Hu J, Chen JX. Cost-utility analysis of 5 kinds of GLP-1RAs in the treatment of poorly controlled type 2 diabetes mellitus treated with Metformin. China Pharm. 2024;35(6):718\u201323.","journal-title":"China Pharm"},{"key":"1927_CR30","doi-asserted-by":"crossref","unstructured":"Yao H, Zhang A, Li D, Wu Y, Wang C-Z, Wan J-Y et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ. 2024.","DOI":"10.1136\/bmj-2023-076410"},{"issue":"1\u20132","key":"1927_CR31","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.mce.2008.11.018","volume":"297","author":"D Russell-Jones","year":"2009","unstructured":"Russell-Jones D. Molecular, Pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue. Mol Cell Endocrinol. 2009;297(1\u20132):137\u201340.","journal-title":"Mol Cell Endocrinol"},{"issue":"11","key":"1927_CR32","doi-asserted-by":"publisher","first-page":"e0278293","DOI":"10.1371\/journal.pone.0278293","volume":"17","author":"J Loftus","year":"2022","unstructured":"Loftus J, Yaworsky A, Roland CL, Turner-Bowker D, McLafferty M, Su S, Lamoureux RE. Experience of switching from a daily to a less frequent administration of injection treatments. PLoS ONE. 2022;17(11):e0278293.","journal-title":"PLoS ONE"},{"key":"1927_CR33","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/dmrr.2827","volume":"32","author":"J Weng","year":"2016","unstructured":"Weng J, Ji L, Jia W, et al. Standards of care for type 2 diabetes in China. Diabetes Metab Res Rev. 2016;32:442\u201358.","journal-title":"Diabetes Metab Res Rev"},{"key":"1927_CR34","doi-asserted-by":"crossref","unstructured":"Yao H, Zhang A, Li D et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis[J]. BMJ, 2024, 384.","DOI":"10.1136\/bmj-2023-076410"},{"issue":"1","key":"1927_CR35","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s12889-019-6569-8","volume":"19","author":"W Mao","year":"2019","unstructured":"Mao W, Yip CW, Chen W. Complications of diabetes in china: health system and economic implications. BMC Public Health. 2019;19(1):269.","journal-title":"BMC Public Health"},{"issue":"4","key":"1927_CR36","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s13300-024-01540-7","volume":"15","author":"Y Cui","year":"2024","unstructured":"Cui Y, Yao J, Qiu X, Guo C, Kong D, Dong J, Liao L. Comparative efficacy and safety of Tirzepatide in Asians and Non-Asians with type 2 diabetes mellitus: A systematic review and Meta-Analysis. Diabetes Ther. 2024;15(4):781\u201399.","journal-title":"Diabetes Ther"},{"key":"1927_CR37","doi-asserted-by":"crossref","unstructured":"Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational global attitudes of patients and physicians in insulin therapy study. Diabet Med. 2012-;29(5):682\u20139.","DOI":"10.1111\/j.1464-5491.2012.03605.x"},{"issue":"5","key":"1927_CR38","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/j.1464-5491.2012.03605.x","volume":"29","author":"M Peyrot","year":"2012","unstructured":"Peyrot M, Barnett AH, Meneghini LF, et al. Insulin adherence behaviours and barriers in the multinational global attitudes of patients and physicians in insulin therapy study[J]. Diabet Med. 2012;29(5):682\u20139.","journal-title":"Diabet Med"},{"issue":"10","key":"1927_CR39","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1111\/ijcp.12691","volume":"69","author":"CJ Ng","year":"2015","unstructured":"Ng CJ, Lai PS, Lee YK, Azmi SA, Teo CH. Barriers and facilitators to starting insulin in patients with type 2 diabetes: a systematic review. Int J Clin Pract. 2015;69(10):1050\u201370.","journal-title":"Int J Clin Pract"},{"issue":"8","key":"1927_CR40","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s40273-013-0066-1","volume":"31","author":"VK Brennan","year":"2013","unstructured":"Brennan VK, Dixon S. Incorporating process utility into quality adjusted life years: a systematic review of empirical studies. PharmacoEconomics. 2013;31(8):677\u201391.","journal-title":"PharmacoEconomics"},{"key":"1927_CR41","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s40273-020-00922-6","volume":"38","author":"M Willis","year":"2020","unstructured":"Willis M, Fridhammar A, Gundgaard J, et al. Comparing the cohort and Micro-Simulation modeling approaches in Cost-Effectiveness modeling of type 2 diabetes mellitus: A case study of the IHE diabetes cohort model and the economics and health outcomes model of T2DM. PharmacoEconomics. 2020;38:953\u201369.","journal-title":"PharmacoEconomics"},{"issue":"3","key":"1927_CR42","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1080\/14737167.2024.2420654","volume":"25","author":"ATN Toan","year":"2025","unstructured":"Toan ATN, Phung TL, Dang TT, et al. Cost-effectiveness of sodium-glucose cotransporter 2 inhibitors in the treatment of chronic kidney disease: a systematic review. Expert Rev PharmacoEcon Outcomes Res. 2025;25(3):307\u201321.","journal-title":"Expert Rev PharmacoEcon Outcomes Res"},{"issue":"5","key":"1927_CR43","first-page":"672","volume":"74","author":"Y Wang","year":"2025","unstructured":"Wang Y, Xia C, Li M, Xu G. Comparison of the effects of SGLT-2i versus GLP-1RA on cardiovascular and renal outcomes in patients with type 2 diabetes, based on baseline renal function. Diabetes. 2025;74(5):672\u201381.","journal-title":"Diabetes"}],"container-title":["Diabetology &amp; Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-025-01927-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-025-01927-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-025-01927-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T03:56:58Z","timestamp":1757476618000},"score":1,"resource":{"primary":{"URL":"https:\/\/dmsjournal.biomedcentral.com\/articles\/10.1186\/s13098-025-01927-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1927"],"URL":"https:\/\/doi.org\/10.1186\/s13098-025-01927-x","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]},"assertion":[{"value":"20 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"This systematic review was limited to published research and did not involve human participants, and as such, human participant protection was not required.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human participant protection"}}],"article-number":"358"}}